This investment comes as LGM Pharma experiences sustained growth in prescription drug projects, including 505(b)(2) and Abbreviated New Drug Application (ANDA) programs. The Rosenberg facility ...

Pakistan's pharmaceutical industry, valued at Rs. 748 billion, faces challenges with API imports. Localizing API production could enhance economic stability and healthcare affordability.

LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today reported strong growth in 2022 in both its long-established Active Pharmaceutical Ingredient ...

AbbVie’s North Chicago expansion adds two state-of-the-art API plants intended to support next-generation neuroscience and obesity portfolios via advanced manufacturing technologies and artificial ...

Throughout 2025, drugmakers of all stripes have collectively poured billions of dollars into U.S. manufacturing investments. Many of those projects have centered on later stages of the production ...

Astorg, EQT, New Mountain Capital and TA Associates are among the PE firms buying and selling active pharmaceutical ingredient assets.

DUBLIN, May 10, 2021 /PRNewswire/ -- The "Global Active Pharmaceutical Ingredient Market (2020-2025) by Type, Molecule, Product Type, Formulation Type, Manufacturing Type, Synthesis Type, Drug Type, ...

Strengthens service portfolio to meet growing demand for early-phase clinical trial support and innovation CRYSTAL LAKE, Ill.--(BUSINESS WIRE)-- Aptar Pharma, a global leader in drug delivery and ...

BOCA RATON, Fla.--(BUSINESS WIRE)--LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today announced an investment of over $6 million to expand its ...

LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today announced an investment of over $6 million to expand its Rosenberg, Texas manufacturing ...